Edgewell Personal Care Cuts FY26 Earnings Outlook To Reflect Sale Of Feminine Care Business

Edgewell cut its fiscal 2026 EPS guidance to $0.55–$0.95 from $1.10–$1.50 after classifying the Feminine Care business as discontinued, and now expects adjusted EPS of $1.70–$2.10 versus prior $2.15–$2.55, a $0.44 per-share reduction tied to the divestiture and related restructuring, Sun Care reformulation and other costs. The company reaffirmed annual net sales growth of ~0.5%–3.5% and projects capex around 3%–3.5% of sales, while the board declared a $0.15 quarterly dividend payable April 8 (record March 6). Shares were modestly weaker in pre-market trade (down ~2.98% at $20.13), reflecting investor reaction to the guidance downgrade and discontinued-operations impact.

Analysis

Market structure: The immediate winners are the acquirer of the Feminine Care business and larger, diversified personal-care incumbents (e.g., KMB, PG) that can absorb pricing/mix pressure; EPC equity and short-duration creditors are losers as guidance cut reduces visible earnings by ~42% at the midpoint (from $1.30 to $0.75). Reaffirmed revenue growth of 0.5%–3.5% suggests demand is stable but margins will be the battleground as Sun Care reformulation and restructuring push costs into FY26, compressing near-term EBITDA by an estimated $0.40–$0.50/sh annualized if not offset.

Risks: Tail risks include failed integration/regulatory snafus at the buyer, sun‑care reformulation recalls, or a liquidity squeeze if share price breaches covenant levels for any credit instruments; low-probability but high-impact downside could exceed 30% if two of these materialize. Time horizons: expect immediate volatility (days) of 3–8%, short‑term (weeks–months) realized EPS and margin updates, and long‑term (quarters) clarity as cost saves and divestiture proceeds are deployed; watch adjusted EPS movement toward $2.00 as a key 2–3 quarter indicator.

Trade implications: Tactical short bias on EPC (size 1.5%–3% portfolio) via defined‑risk options to capture near-term repricing; implement pair trade long KMB (2% weight) vs short EPC (2%) over 3–6 months to play relative margin resilience. Options: buy Jun 2026 $18/$15 put spread on EPC (defined risk) and consider selling 1–2% covered calls on KMB to fund carry; trim mid‑cap personal care exposure by 2–4% and reallocate to large-cap staples (PG/KMB) with target 6–12 month horizon.

Contrarian angles: The market may be over-penalizing a bookkeeping/classification hit—core adjusted EPS guidance of $1.70–$2.10 implies underlying cash flow remains; if management deploys divestiture proceeds to buybacks/dividend or achieves >$0.30/sh restructuring run‑rate savings, upside re-rating is possible within 2 quarters. Historical parallels (post‑divestiture re-rating events) suggest a mean reversion snapback if adjusted EPS rebounds above $2.00 and net leverage falls below 2.5x; set explicit cover triggers to avoid being swept up if that occurs.

Key Decisions for Investors

• Establish a 2% portfolio short position in EPC via a Jun-2026 $18/$15 put spread (defined downside) to capture near-term repricing; add if EPC trades below $18 and trim if EPC rallies above $24 (cover threshold).
• Implement a relative-value pair: long 2% KMB and short 2% EPC for 3–6 months to play superior pricing/margin durability at KMB; close the pair if KMB/EPC spread narrows by >8% or if EPC adjusted EPS recovers to >$2.00 in two consecutive quarters.
• Reduce mid-cap personal care exposure by 3% and redeploy into large-cap staples (add 1–2% each to PG and KMB) over the next 2 weeks to lower margin and execution risk while retaining sector exposure.
• Monitor three catalysts over the next 60–90 days and act: (1) EPC quarterly update for restructuring run‑rate and Sun Care cost timing, (2) disclosure of buyer integration plan for Feminine Care, and (3) any change to dividend policy; if adjusted EPS guidance is raised toward prior midpoint (>$2.00) within two quarters, neutralize shorts and redeploy capital to long EPC exposure up to 1%.